VOR (Vor Biopharma) Moat Score: 3/10 (As of Jul. 11, 2026)


VOR Vor Biopharma Inc VOR
32 GF Score
Price $19.14
! 3 Warning Signs
View Full Analysis

What is Vor Biopharma Moat Score?

Vor Biopharma VOR -3.09% 32 Moat Score is 3 as of Jul. 11, 2026. GuruFocus rates VOR with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,395 Biotechnology companies, Vor Biopharma ranks better than 75.56% on this metric.

Vor Biopharma has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Vor Biopharma has No Moat: Vor Biopharma Inc has very weak competitive advantages. While it has some valuable intellectual property in biotech, the company is in early stages with limited market share and lacks significant customer loyalty or regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Vor Biopharma might have No Moat - Very weak/transient advantages.

Vor Biopharma  (NAS:VOR) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Vor Biopharma Moat Score Related Terms

VOR vs ODTX, ANNX, ABUS: Moat Score Comparison

For the Biotechnology subindustry, Vor Biopharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vor Biopharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vor Biopharma's Moat Score distribution charts can be found below:

* The bar in red indicates where Vor Biopharma's Moat Score falls into.


VOR
32GF Score
Vor Biopharma Inc VOR
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Vor Biopharma (VOR) has a Moat Score of 3 as of Jul. 11, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Vor Biopharma ranks #341 out of 1395 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Vor Biopharma's Moat Score too high?
Vor Biopharma's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Vor Biopharma's value of 3 is 50% above this industry median. Based on the distribution chart, Vor Biopharma ranks #341 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vor Biopharma has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Vor Biopharma's Moat Score compare to ODTX and ANNX?
According to the Biotechnology industry distribution chart, Vor Biopharma ranks #341 out of 1395 companies for Moat Score. This places Vor Biopharma in the top 24% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Vor Biopharma's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vor Biopharma's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vor Biopharma's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vor Biopharma stock overvalued right now?
Vor Biopharma (VOR) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Vor Biopharma's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Vor Biopharma (VOR), the current Moat Score is 3 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vor Biopharma Business Description

Address 500 Boylston Street, Suite 1350, Boston, MA, USA, 02116
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
32GF Score

Get the complete analysis for VOR

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.14
Price